To validate whether recurrent AITL mutations are tumor‐specific, we performed flow sorting for 10 AITL including neoplastic‐cells (CD3+/PD1+), myeloid (CD68+/CD11B+), and B‐cells (CD3‐/CD79B+) and WES was performed on the tumor enriched cell fraction for nine AITLs (Figure S4A, Table S3). The gene discussed is CD79B; the disease is angioimmunoblastic T-cell lymphoma.